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Summary
Objective: Aggrecanase-1 [a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4] and aggrecanase-2 (ADAMTS-5)
have been named for their ability to degrade the proteoglycan aggrecan. While this may be the preferred substrate for these enzymes,
they are also able to degrade other proteins. The aim of this work was to determine whether the aggrecanases could degrade biglycan
and decorin.
Methods: Biglycan, decorin and aggrecan were puriﬁed from human and bovine cartilage and subjected to degradation by recombinant
aggrecanase-1 or aggrecanase-2. In vitro degradation was assessed by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS/
PAGE) and immunoblotting, and the cleavage site in biglycan was determined by N-terminal amino acid sequencing. SDS/PAGE and immu-
noblotting were also used to assess in situ degradation in both normal and arthritic human articular cartilage.
Results: Both aggrecanase-1 and aggrecanase-2 are able to cleave bovine and human biglycan at a site within their central leucine-rich
repeat regions. Cleavage occurs at an asparagineecysteine bond within the ﬁfth leucine-rich repeat. In contrast, the closely related proteo-
glycan decorin is not a substrate for the aggrecanases. Analysis of human articular cartilage from osteoarthritic (OA) and rheumatoid arthritic
(RA) joints showed that a biglycan degradation product of equivalent size is present in the extracellular matrix. No equivalent degradation
product was, however, detectable in normal adult human articular cartilage.
Conclusion: Biglycan, which is structurally unrelated to aggrecan, can act as a substrate for aggrecanase-1 and aggrecanase-2, and these
proteinases may account for at least part of the biglycan degradation that is present in arthritic cartilage.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Biglycan and decorin belong to the family of small leucine-
rich repeat proteoglycans (SLRPs). The SLRPs are char-
acterized by the presence of 6e10 adjacent leucine-rich
repeats ﬂanked by cysteine-rich domains1,2. Usually they
are substituted with chondroitin sulfate, dermatan sulfate
or keratan sulfate chains, which distinguish them from the
larger family of leucine-rich repeat proteins which share
the same leucine-rich motif3. The presence of the con-
tiguous leucine-rich repeats causes the proteins to adopt
a curved or horseshoe-like conformation4,5, which is thought
to be responsible for their functional ability to interact with
other proteins within the extracellular matrix of tissues.
Biglycan and decorin are structurally similar, with both
possessing 10 leucine-rich repeats and chondroitin sulfate
or dermatan sulfate in the amino terminal regions of their
core proteins6. In the case of biglycan there are two attach-
ment sites for chondroitin sulfate or dermatan sulfate,
whereas decorin has only one such site7,8. The presence
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Received 6 February 2006; revision accepted 16 May 2006.1of chondroitin sulfate or dermatan sulfate varies between
tissues, though the functional signiﬁcance of this change
is unclear. Both proteoglycans can interact with a variety
of other proteins, including growth factors9e12 and colla-
gens13,14, and in so doing they can inﬂuence both the integ-
rity of the extracellular matrix and its metabolism. The
function of the two proteoglycans is not, however, equiva-
lent, as their ability to interact with other proteins does
vary. While decorin interacts with the surface of the ﬁbrils
formed by types I and II collagen15e17, biglycan shows
a preferential interaction for type VI collagen and aids in
the formation of the type VI collagen network14,18.
The structure of biglycan and decorin may vary with age
in both their glycosaminoglycan chains and their core pro-
teins. The chondroitin sulfateedermatan sulfate chains
may vary in length, position of sulfation and degree of ur-
onic acid epimerization19, whereas the core proteins may
undergo proteolytic modiﬁcation20. Such proteolytic modiﬁ-
cation is most apparent in biglycan, which undergoes cleav-
age within its amino terminal domain resulting in the
separation of the terminal peptide bearing the glycosamino-
glycan chains from the remainder of the core protein. The
‘‘no glycan’’ forms of biglycan appear to accumulate in the
extracellular matrix with age20. Similar proteolytic process-
ing also occurs in decorin, although to a lesser extent21.
More extensive proteolytic modiﬁcation of the core proteins147
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arthritic joints22,23.
At present it is not clear whether the proteolytic modiﬁca-
tion of biglycan and decorin alters their function, though
one might expect it to if both the glycosaminoglycan chains
and the core protein contribute to the normal functions of
the proteoglycans. It is also not clear which proteinases are
responsible for the proteolytic modiﬁcation, though onemight
predict the involvement of proteinases that are active in the
extracellular matrix and that are secreted by the constituent
cells. Metalloproteinases belonging to the matrix metallopro-
teinase (MMP) and a disintegrin and metalloproteinase
(ADAM) families form ideal candidates for this role24e26.
Of particular interest are the aggrecanases, members of
the ADAM with thrombospondin motifs (ADAMTS) fam-
ily27e29. Aggrecanase-1 (ADAMTS-4)30 and aggrecanase-
2 (ADAMTS-5)31 are normally associated with their ability
to degrade aggrecan32,33, the major proteoglycan in the ex-
tracellular matrix of hyaline cartilages. However, they have
also been described to degrade other substrates (Table I),
and would be in the correct milieu to degrade the SLRPs.
The purpose of this study was to determine whether ag-
grecanase-1 or aggrecanase-2 is able to degrade biglycan
or decorin, and assess whether the products of such degra-
dation are present within the extracellular matrix of articular
cartilage.
Methods
SOURCE OF CARTILAGE
Normal human articular cartilage was obtained from the
femoral condyles of the knee at the time of autopsy from
individuals, ranging in age from 7 months to 61 years,
who had no evidence of a joint disorder. Cartilage was
taken with the permission of the chief pathologist from indi-
viduals where the next of kin had given consent for a com-
plete autopsy. Human articular cartilage was also obtained
from the knees of individuals aged 50e75 years, who had
undergone total knee replacement for osteoarthritis (OA)
or rheumatoid arthritis (RA). Normal bovine nasal cartilage
from animals aged 18 months to 2 years was obtained
from the abattoir at the time of slaughter.
PREPARATION OF PROTEOGLYCANS
Biglycan and decorin were puriﬁed from juvenile human
cartilage as previously described7. Brieﬂy, the cartilage
was extracted with 4 M guanidinium chloride in thepresence of proteinase inhibitors and the extract was sub-
jected to cesium chloride density gradient centrifugation un-
der dissociative conditions at a starting density of 1.4 g/ml.
Aggrecan was recovered from the bottom of the density gra-
dient, while a preparation enriched in the SLRPs was recov-
ered from the center. The SLRPs were further puriﬁed by
anion exchange through DEAE-Sephacel and subsequent
gel ﬁltration chromatography through Sepharose CL-4B34.
Bovine biglycan and decorin were a kind gift from
Dr L. Rosenberg (Monteﬁore Hospital, New York, NY).
SOURCE OF AGGRECANASE
Recombinant human aggrecanase-1 and aggrecanase-2
were a kind gift from Dr J. Barnett (Roche Biosciences, Palo
Alto, CA). They had been prepared by infecting insect cells
with a recombinant baculovirus containing the full length ag-
grecanase cDNA35. The aggrecanases were puriﬁed from
the culturemediumby ionexchange chromatography through
SP-Sepharose FF35. The molecular form of the recombinant
aggrecanaseswasassessedby sodiumdodecyl sulfate/poly-
acrylamide gel electrophoresis (SDS/PAGE) analysis and im-
munoblotting, as describedbelow for analysis of proteoglycan
degradation products. The primary antibodies used for analy-
sis were raised in rabbits against synthetic peptides conju-
gated to ovalbumin36. The peptide sequences were derived
from the published amino acid sequences of aggrecanase-1
(FASLS) and aggrecanase-2 (SISRA), and correspond to
the amino terminal sequences of the mature proteinases fol-
lowing furin activation37.
PROTEOGLYCAN DEGRADATION BY AGGRECANASE
Biglycan, decorin or aggrecan was incubated with aggre-
canase-1 or aggrecanase-2 in 50 mM Tris/HCl, 250 mM
NaCl, 5 mM CaCl2 at either pH 7.5 or pH 8.5
35. The proteo-
glycans were dissolved at 1 mg/ml in the digestion buffer,
and incubation was carried out overnight at 37(C with suf-
ﬁcient aggrecanase to give limit digests. In some experi-
ments incubations were carried out in the presence of
either o-phenanthroline or ethylenediaminetetraacetic acid
(EDTA) (1 mM or 10 mM ﬁnal concentration, respectively).
CHONDROITINASE AND KERATANASE TREATMENT
Prior to subsequent analyses by SDS/PAGE, biglycan
and decorin or their degradation products were treated
with chondroitinase ABC (0.05 mU/mg proteoglycan) in
100 mM Tris/HCl, 100 mM sodium acetate, pH 7.3, atTable I
Sites of aggrecanase cleavage in proteins
Molecule Species Sequence Aggrecanase Reference
Aggrecan* Human ITEGEeARGSV 1, 2
33
Human ASELEeGRGTI 1, 2 33
Human FKEEEeGLGSV 1, 2 33
Human PTAQEeAGEGP 1, 2 33
Human TISQEeLGQRP 1, 2 33
Versican Human PEAAEeARRGQ 1 52
Brevican Rat AVESEeSRGAI 1 53
Aggrecanase-1 Human GSFRKeFRYGY 1 54
GSALTeFREEQ 1 54
Aggrecanase-2 Human VRIPEeGATHI 2 55
a2M ESDVMeGRGHA 1, 2
56
Biglycan Bovine LRNMNeCIEMG 1, 2 This work
*Equivalent cleavage sites have also been reported in bovine aggrecan61,62.
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products, chondroitinase treatment was preceded by treat-
ment with keratanase II (0.005 mU/mg proteoglycan) in
10 mM sodium acetate, pH 6.0, at 37(C overnight.
ANALYSIS OF PROTEOGLYCAN DEGRADATION
Proteoglycans or their aggrecanase-derived degradation
products (1 mg) were analyzed by SDS/PAGE using
4e20% (w/v) gradient gels (Novex NuPage BiseTris gels;
Invitrogen), according to the manufacturer’s instructions.
Fractionated proteins were then transferred to nitrocellulose
membranes (Bio-Rad) by electroblotting38 and identiﬁed by
immunoblotting. Following blocking of the membranes in
5% skim milk (Carnation Instant Milk Powder), they were
exposed to primary antibodies recognizing either the car-
boxy terminus of biglycan or decorin20 or a mixture of
epitopes in the G3 domain of aggrecan39. Immunoreactive
proteins were identiﬁed using a secondary biotinylated
anti-rabbit IgG, a streptavidin-biotinylated horseradish per-
oxidase complex, and a chemiluminescence substrate, fol-
lowed by exposure to Hyperﬁlm (Amersham). In addition,
extracts of normal and arthritic human articular cartilage
were analyzed in an analogous manner for degradation
products of biglycan.
N-TERMINAL AMINO ACID SEQUENCING
Degradation products resulting from aggrecanase treat-
ment of biglycan were resolved by SDS/PAGE following
chondroitinase ABC treatment, as described above. Frac-
tionated proteins were then transferred to polyvinylidene
diﬂuoride membranes (Immobilon P, Bio-Rad) by electro-
blotting. The membranes were then stained brieﬂy with
0.1% Coomassie Blue R-250 until bands were visible,
then brieﬂy destained in 50% methanol, 10% acetic acid,
and subsequently washed well with water. Bands corre-
sponding to biglycan degradation products were excised
and analyzed directly by sequential Edman degradation to
determine the amino terminal amino acid sequence40.
Sequencing was carried out by the Sheldon Biotechnology
Centre, McGill University.
Results
When degradation products of bovine decorin were ana-
lyzed by SDS/PAGE and immunoblotting, there was no ev-
idence for aggrecanase-1-mediated degradation of the
decorin core protein. The intact decorin migrated with a mo-
lecular size of about 70 kDa prior to chondroitinase ABC
treatment [Fig. 1(A), lane 1] and about 48 kDa following
chondroitinase ABC treatment [Fig. 1(A), lane 2]. Following
aggrecanase treatment, the decorin core protein possessed
a size analogous to that of the core protein prior to treat-
ment [Fig. 1(A), lane 3]. The treated decorin core protein
migrated slightly faster than that present without treatment
due to the presence of an endoglycosidase activity pro-
duced by the insect cells used to generate the recombinant
proteinase41.
In contrast, aggrecanase-1 treatment did result in pro-
teolytic cleavage of the bovine biglycan core protein. While
intact biglycan is not visualized with the antibody used
[Fig. 1(B), lane 1], the chondroitinase-treated core protein
migrates with a molecular size of about 45 kDa
[Fig. 1(B), lane 3]. Following aggrecanase treatment a deg-
radation product of about 27 kDa was visualized byimmunoblotting [Fig. 1(B), lane 2]. However, even under
conditions of limiting digestion degradation did not appear
to be complete, as chondroitinase treatment still revealed
the presence of the intact core protein [Fig. 1(B), lane 4].
aggrecanase-1
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Fig. 1. Effect of aggrecanase-1 on bovine decorin and biglycan.
The action of aggrecanase-1 on bovine decorin and biglycan was
studied by SDS/PAGE and immunoblotting. (A) Lane 1, intact
decorin; lane 2, intact decorin following chondroitinase treatment;
lane 3, aggrecanase-treated decorin following chondroitinase treat-
ment. (B) Lane 1, intact biglycan; lane 2, aggrecanase-treated
biglycan; lane 3, intact biglycan following chondroitinase treatment;
lane 4, aggrecanase-treated biglycan following chondroitinase
treatment; lane 5, biglycan incubated with aggrecanase in the pres-
ence of o-phenanthroline; lane 6, biglycan incubated with aggreca-
nase in the presence of o-phenanthroline and subsequent
chondroitinase treatment.
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was the same both before and after chondroitinase treat-
ment, as expected for a fragment derived from the car-
boxyl terminus of the molecule. The cleavage of biglycan
by aggrecanase was completely prevented by the pres-
ence of o-phenanthroline, a zinc-chelating inhibitor of met-
alloproteinases. Under these conditions only the intact
biglycan core protein was evident [Fig. 1(B), lane 6]. A
similar result was obtained when incubation was carried
out in the presence of EDTA, another metal-chelating in-
hibitor of metalloproteinases.
Aggrecanase-1 treatment of human biglycan gave similar
results to its bovine counterpart, with the carboxy terminal
degradation product of about 27 kDa being detected
(Fig. 2, lane 1). This and the previous studies on bovine bi-
glycan had been carried out at pH 8.5, the pH optimum of
the aggrecanases in vitro42. It was therefore important to
establish whether biglycan cleavage could also occur at
a more physiologically relevant pH. Incubation with aggre-
canase-1 at pH 7.5 (Fig. 2, lane 2) gave identical results
to those obtained at pH 8.5. It was, however, apparent
that human biglycan cleavage was more extensive than
that of bovine biglycan, with all the biglycan now undergoing
degradation.
Aggrecanase-2 was also able to cleave the human bigly-
can with equal efﬁciency at both pH 8.5 and 7.5 (Fig. 2,
lanes 3 and 4). The degradation product was of identical
pH
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Fig. 2. Effect of aggrecanases on human biglycan. Aggrecanase-1
or aggrecanase-2 was incubated with human biglycan at either pH
8.5 or pH 7.5, and the products analyzed by SDS/PAGE and immu-
noblotting. All digestion mixtures were treated with chondroitinase
prior to analysis. Lane 1, biglycan treated with aggrecanase-1 at
pH 8.5; lane 2, biglycan treated with aggrecanase-1 at pH 7.5;
lane 3, biglycan treated with aggrecanase-2 at pH 8.5; lane 4, bigly-
can treated with aggrecanase-2 at pH 7.5.size to that obtained with aggrecanase-1. However, in
contrast to aggrecanase-1, aggrecanase-2 gave incomplete
degradation of biglycan, even under conditions of limit di-
gestion. The diminished ability of aggrecanase-2 to cleave
biglycan appears to be substrate speciﬁc, as when identical
enzyme to substrate ratios were used with bovine aggre-
can, both aggrecanases resulted in extensive cleavage of
the core protein (Fig. 3). Moreover, when products contain-
ing the aggrecan G3 domain were visualized by immuno-
blotting, the extent of degradation appeared to be greater
for aggrecanase-2 than aggrecanase-1. As with aggreca-
nase-1, there was no evidence that aggrecanase-2 could
cleave decorin (data not shown).
As the substrate speciﬁcity of aggrecanases can depend
upon their C-terminal processing, the molecular form of ag-
grecanases used in this study was established by SDS/
PAGE and immunoblotting. Aggrecanase-1 was shown to
be present in the recombinant enzyme preparation as a ma-
jor component of about 70 kDa [Fig. 4(A)], whereas aggre-
canase-2 was present as two components of about 56 and
62 kDa [Fig. 4(B)].
To investigate whether the aggrecanase-mediated bigly-
can degradation product was present in normal human
articular cartilage, tissue ranging from the young juvenile
aggrecanase 1 2
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Fig. 3. Effect of aggrecanases on aggrecan. Aggrecanase-1 or
aggrecanase-2 was incubated with bovine aggrecan at pH 7.5,
and the products analyzed by SDS/PAGE and immunoblotting
using an antibody to the aggrecan G3 domain. The digestion
mixtures were treated with keratanase and chondroitinase prior to
analysis. Lane 1, intact aggrecan; lane 2, aggrecan treated with
aggrecanase-1; lane 3, aggrecan treated with aggrecanase-2.
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analyzed by SDS/PAGE and immunoblotting. The biglycan
degradation product was not detected in any normal adult
cartilage examined, nor was it present in a 7-year-old juve-
nile cartilage [Fig. 5(A)]. However, a biglycan degradation
product of equivalent size was present as a minor compo-
nent in cartilage from a 7-month-old. In contrast, the bigly-
can degradation product was detected in extracts of adult
human articular cartilage derived from individuals with either
OA or RA [Fig. 5(B)]. In the mature cartilages, biglycan
exists predominantly in three forms of 40e50 kDa. These
have previously been shown to represent intact biglycan
and two N-terminally processed forms of the molecule20.
Such processing is not aggrecanase-mediated43.
To establish the cleavage site at which the aggrecanases
are acting on biglycan, the 27 kDa degradation product
resulting from aggrecanase-1 action on bovine biglycan
was isolated by SDS/PAGE and subjected to N-terminal
amino acid sequencing. A single sequence was obtained
for 10 cycles, XIEMGGNPLE.Comparisonwith the published
37
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Fig. 4. Analysis of aggrecanase composition. The aggrecanase
preparations were analyzed by SDS/PAGE and immunoblotting,
using antibodies speciﬁc for each proteinase. (A) Aggrecanase-1;
(B) aggrecanase-2.amino acid sequence of bovine biglycan showed that the un-
identiﬁed initial residue corresponds to cysteine, with cleav-
age having occurred between Asn149 and Cys150.
Discussion
Both aggrecanase-1 and aggrecanase-2 cleave bovine
and human biglycan near the beginning of their ﬁfth
leucine-rich repeat domain. The amino acid sequence sur-
rounding the cleavage site is conserved in all species de-
scribed to date e mouse, rat, human, bovine6,44e46, dog
A
kDa
age (yrs) 1 226 39 61
220
120
100
80
60
50
40
30
20
1 2 3 4 5
B
kDa
220
120
100
80
60
50
40
30
20
1 2 3 4 5 6
OAarthritis OA OA RA RA RA
Fig. 5. Analysis of biglycan in normal and arthritic human cartilage.
Extracts of human articular cartilage were analyzed by SDS/PAGE
and immunoblotting using an antibody to biglycan. All extracts were
treated with chondroitinase prior to analysis. (A) Samples were
from normal individuals aged: (1) 7 months, (2) 6 years, (3) 22
years, (4) 39 years, and (5) 61 years. (B) Samples were from indi-
viduals with arthritic joints aged: (1) 73 years, (2) 75 years, (3) 74
years, (4) 50 years, (5) 77 years and (6) 62 years. Samples 1e3
were from OA cartilage, and samples 4e6 were from RA cartilage.
Arrow indicates the position of the biglycan cleavage product.
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and occurs between asparagine and cysteine residues
(Fig. 6). Cleavage generates a carboxy terminal fragment
of about 27 kDa, commencing with the cysteine residue
and ending at the carboxy terminus of the mature biglycan
core protein. It is not clear if this is the only cleavage site
within biglycan, as amino terminal fragments cannot be de-
tected by the carboxy terminal antibody used for immuno-
blotting. However, no other sequence predicted to be
compatible with an aggrecanase cleavage site occurs else-
where in the biglycan core protein. The unique leucine-rich
sequence cleaved by the aggrecanases in biglycan is not
conserved in decorin47e49 nor are any consensus aggreca-
nase cleavage sites present. Hence, it is not surprising that
the aggrecanases should fail to cleave decorin. However,
there has been one report that a C-terminally truncated re-
combinant form of aggrecanase-1 will cleave decorin50,
albeit very inefﬁciently, and it is possible that C-terminal
truncation could result in altered substrate speciﬁcity. The
aggrecanase-1 used in the present work was not C-termi-
nally truncated.
The data presented in the present work indicate more
substantial cleavage of human than bovine biglycan. One
contributing factor is probably the decreased substrate to
enzyme ratio used in the human work. Although all diges-
tions were carried out using a constant proteoglycan to ag-
grecanase ratio, the bovine biglycan was pure whereas the
human biglycan was present together with decorin, so low-
ering its effective concentration. It is unlikely that the data
reﬂect a true species difference, as the amino acid se-
quence surrounding the cleavage site is identical. However,
it is possible that cysteine modiﬁcation could occur in situ at
the aggrecanase cleavage site, and that differences in such
modiﬁcation could occur between the two biglycan prepara-
tions so inﬂuencing their susceptibility to cleavage. Also,
one cannot exclude the possibility that biglycan forms
dimers in a similar manner to decorin5,51, but that there
are differences in dimer conformation between the two
biglycan preparations that inﬂuence access of the aggreca-
nases to their cleavage site.
Initially, aggrecanases were characterized by their ability
to cleave aggrecan. Both aggrecanase-1 and aggrecanase-
2 cleave aggrecan at the same ﬁve sites33, each following
a glutamic acid residue (Table I). Aggrecanase-1 is also
able to cleave other members of the hyalectin family of
proteoglycans to which aggrecan belongs, with single
cleavage sites having been identiﬁed in both versican52
and brevican53. These cleavage sites also occur following
a glutamic acid residue. Recently it has been shown that
the aggrecanases can cleave protein substrates other
than proteoglycans. The ﬁrst such sites were identiﬁed in
aggrecanase-1 and aggrecanase-2 themselves following
autocatalytic processing54,55. Perhaps unexpectedly, the
cleavages in aggrecanase-1 did not occur following a gluta-
mic acid residue. A similar situation has also been shown to
Fig. 6. Schematic representation of biglycan and its aggrecanase
cleavage site. Biglycan is depicted as a line representing its mature
core protein, with the location of the 10 leucine-rich repeats (ﬁlled
boxes) and the ﬂanking disulﬁde-bonded domains (open boxes) be-
ing indicated. The location of the aggrecanase cleavage site and its
surrounding amino acid sequence are also indicated.occur in a2-macroglobulin (a2M), where cleavage follows
a methionine residue, with both aggrecanase-1 and aggre-
canase-2 being active at this site56. Thus, biglycan repre-
sents another molecule in which the aggrecanases can
cleave following a residue other than glutamic acid. At pres-
ent there is no obvious relationship between the different
cleavage sites, and it is not clear how the different sites
may vary in their avidity toward cleavage.
Where studied, aggrecanase-1 and aggrecanase-2 ap-
pear to have identical substrate speciﬁcity, though the pres-
ent work indicates that they do not necessarily cleave all
sites with equal efﬁciency. A similar conclusion had been
previously reported for cleavage of aggrecan35. In the
case of aggrecan, aggrecanase-2 performs more extensive
degradation, whereas with biglycan aggrecanase-1 is more
active. It is possible that this difference may not be an
innate property of the catalytic domain of the proteinases,
but rather a reﬂection of their molecular state. Aggreca-
nase-1 has been shown to undergo initial proteolytic
activation by cleavage within its amino terminal region by
a furin-like proteinase57. Subsequently, autocatalytic cleav-
age can result in carboxy terminal truncation of the aggreca-
nase58, and with such processing the afﬁnity of the enzyme
for cleavage at different sites does change50. In the present
work, the size of the aggrecanase-1 is compatible with only
amino terminal activation. The aggrecanase-2 used in the
present work was present as two components, both of
which were smaller than the aggrecanase-1. Such sizes
are compatible with carboxy terminal truncation, and this
could contribute to the altered substrate reactivity. Thus
one cannot categorically state that equivalent forms of
aggrecanase-1 and aggrecanase-2, whether intact or
C-terminally truncated, will also show altered substrate
reactivity.
Biglycan degradation products of a size compatible with
aggrecanase cleavage appear to be a feature of adult hu-
man cartilage from arthritic joints but not that from normal
joints. This is not too surprising as increased expression
of aggrecanase via cytokine stimulation is associated with
the arthritic joints59. A similar biglycan degradation product
was also detected in the epiphyseal cartilage of a young ju-
venile human. This is a period of maximal growth rate, when
aggrecanases may contribute toward rapid tissue remodel-
ing. In the case of aggrecan, there is also evidence for pro-
teolytic processing by aggrecanases in the juvenile60. At
present it is unclear whether the biglycan degradation prod-
uct is stably retained within the cartilage matrix or whether it
is lost relatively rapidly. As such, it is possible that the im-
munoblotting analysis performed in this work may not give
a complete reﬂection of the extent of biglycan processing.
One must also accept that size equivalence of the in vitro
and in vivo biglycan degradation products does not categor-
ically prove that they have been generated by cleavage at
identical sites, and conclusive proof awaits conﬁrmation of
the in vivo cleavage site by neoepitope analysis, amino
acid sequencing or mass spectrometry. Anti-neoepitope an-
tibodies have proven to be useful for detecting proteolytic
cleavage products by immunoblotting. However, the pres-
ence of an amino terminal cysteine residue at the aggreca-
nase cleavage site of biglycan poses unique problems for
this technique due to the possibility of oxidation or other
derivatization occurring in situ or during antigen preparation
for antibody production.
It is clear that aggrecanase-mediated cleavage of bigly-
can can occur under physiological conditions, and this
raises the question of whether it is of any functional conse-
quence. While detailed analyses of the structure/function
1153Osteoarthritis and Cartilage Vol. 14, No. 11relationships of biglycan are lacking, it is thought that the
leucine-rich repeat region is responsible for conferring the
ability to interact with other proteins3. As such, cleavage
within the central part of this region might be expected to im-
pair biglycan function. Furthermore, cleavage would result
in separation of the amino terminal portion of the biglycan
core protein bearing the glycosaminoglycan chains from
the remainder of the molecule. Such truncated biglycan
has not been identiﬁed in the cartilage matrix and is likely
lost. Again, this is unlikely to be beneﬁcial to biglycan func-
tion. Thus it is likely that aggrecanase processing of bigly-
can may contribute to cartilage turnover under both
normal and pathological conditions.
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